Related Experiment Video
Updated: Apr 17, 2026
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
Multiple milia formation induced by dovitinib
Dongyun Shin1, Jimyung Seo, Soo Min Kim
1Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Abstract:
Dovitinib is a novel multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-1-3, platelet-derived growth factor receptor-β, Fms-like tyrosine kinase 3, c-Kit and fibroblast growth factor receptor-1-3. This compound is currently being assessed clinically for treatment of various malignancies. In phase I and II clinical trials of dovitinib treatment for renal cell carcinoma, 20% of patients experienced cutaneous adverse events, although the specific type of skin rash was not documented. Here, we report two cases of multiple milia formation induced by dovitinib. We believe our cases are the first report mainly showing non-inflammatory cystic structure.
Insights
Dovitinib, a cancer drug, can cause milia, a type of non-inflammatory skin cyst. This study reports two cases of milia formation linked to dovitinib treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Dovitinib is a multi-target tyrosine kinase inhibitor investigated for various cancers.
- Previous trials noted cutaneous adverse events in 20% of patients receiving dovitinib for renal cell carcinoma.
- The specific type of skin rash associated with dovitinib has not been well-documented.
Observation:
- This report details two cases of patients who developed multiple milia.
- Milia are small, non-inflammatory, white or yellowish cysts on the skin.
- These cases specifically highlight milia formation as a potential adverse event.
Findings:
- Dovitinib treatment was associated with the development of multiple milia in two patients.
- The observed milia were characterized as non-inflammatory cystic structures.
- This represents the first report focusing on dovitinib-induced milia.
Implications:
- Milia formation should be considered a potential cutaneous adverse event of dovitinib therapy.
- Further investigation into the dermatological side effects of dovitinib is warranted.
- This finding may inform clinical monitoring and patient counseling during dovitinib treatment.
